Justin Hovey, MD
Internal Medicine · Dothan, ALNPI 1801970116
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,393 of the $66,596 with a category attached, or 60.7%. 40 manufacturers reported payments, led by Lilly USA, LLC at 40.0% of the total. 2025 is the largest year on record at $29,586, more than ten times the $1,350 reported in 2019. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 747 payments — averaging $89.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$27K
- AbbVie$15K
- Phathom Pharmaceuticals, Inc.$8K
- GSK$7K
- Biohaven Pharmaceuticals, Inc.$3K
- Novo Nordisk$2K
- plus $6K from 34 others
What the payments were for
- Consulting fees$12,15018%
- Speaking & faculty fees$40,39361%
- Travel & lodging$2,2573%
- Food & beverage$11,70818%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$25,813
- VOQUEZNA$7,380
- UBRELVY$7,138
- TRELEGY ELLIPTA$5,750
- NURTEC ODT$2,472
- QULIPTA$675
- XARELTO$364
- SPRAVATO$246
- VYVANSE$125
How this compares
$66,596 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 341 | $421,921 |
| JardianceEmpagliflozin | 155 | $195,431 |
| FarxigaDapagliflozin Propanediol | 129 | $126,628 |
| OzempicSemaglutide | 108 | $107,709 |
| VraylarCariprazine Hcl | 52 | $78,759 |
| EliquisApixaban | 79 | $70,821 |
| XareltoRivaroxaban | 68 | $67,718 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $45,447 |
| KerendiaFinerenone | 49 | $38,415 |
| EntrestoSacubitril/Valsartan | 25 | $35,518 |
| Nurtec OdtRimegepant Sulfate | 25 | $32,903 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $25,804 |
| TrulicityDulaglutide | 24 | $25,093 |
| LinzessLinaclotide | 24 | $20,210 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $20,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $26,616 | $449,951384 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $280 | $205,354174 claims |
| AstraZenecaFarxiga, Symbicort | $360 | $133,207156 claims |
| Novo NordiskOzempic, Levemir | $1,541 | $110,794119 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $393 | $108,693115 claims |
| AbbVieVraylar, Linzess | $15,260 | $98,96876 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $6,647 | $86,454132 claims |
| Johnson & JohnsonXarelto, Invokana | $1,305 | $74,70580 claims |
| BayerKerendia | $437 | $38,41549 claims |
| NovartisEntresto | $198 | $35,51825 claims |
| MerckBelsomra | $672 | $5,81513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Dothan
- Christopher MillerDothan$14K
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
- Rahel AzizMobile$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.